A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
Status:
Recruiting
Trial end date:
2024-11-15
Target enrollment:
Participant gender:
Summary
This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and
cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012
in patients with advanced and/or metastatic solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Pieris Pharmaceuticals, Inc.
Collaborator:
Institut de Recherches Internationales Servier (I.R.I.S.)